← Back to Screener
Adial Pharmaceuticals, Inc (ADIL)
Price$1.62
Favorite Metrics
Price vs S&P 500 (26W)-87.80%
Price vs S&P 500 (4W)-10.53%
Market Capitalization$2.31M
All Metrics
Book Value / Share (Quarterly)$4.75
P/TBV (Annual)1.11x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-5.84
Price vs S&P 500 (YTD)-73.19%
EPS (TTM)$-16.98
10-Day Avg Trading Volume0.09M
EPS Excl Extra (TTM)$-16.98
EPS (Annual)$-11.93
ROI (Annual)-151.18%
Cash / Share (Quarterly)$5.29
ROA (Last FY)-119.54%
EBITD / Share (TTM)$-11.45
ROE (5Y Avg)-308.49%
Cash Flow / Share (Annual)$-5.84
P/B Ratio0.44x
P/B Ratio (Quarterly)1.11x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-22.29x
ROA (TTM)-141.28%
EPS Incl Extra (Annual)$-11.93
Current Ratio (Annual)4.42x
Quick Ratio (Quarterly)4.21x
3-Month Avg Trading Volume0.05M
52-Week Price Return-91.06%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.75
52-Week High$687.50
EPS Excl Extra (Annual)$-11.93
Tangible BV CAGR (5Y)5.84%
26-Week Price Return-83.82%
Quick Ratio (Annual)4.21x
13-Week Price Return-72.21%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.42x
Enterprise Value$-3.568
Book Value / Share Growth (5Y)-7.10%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$5.29
3-Month Return Std Dev9066.83%
Net Income / Employee (TTM)$-2
ROE (Last FY)-151.18%
Net Interest Coverage (Annual)-22.29x
EPS Basic Excl Extra (Annual)$-11.93
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-16.98
ROI (TTM)-182.35%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.75
Price vs S&P 500 (52W)-120.89%
Year-to-Date Return-70.55%
5-Day Price Return3.85%
EPS Normalized (Annual)$-11.93
ROA (5Y Avg)-194.30%
Month-to-Date Return-9.50%
Cash Flow / Share (TTM)$-4.58
EBITD / Share (Annual)$-11.42
ROI (5Y Avg)-308.49%
EPS Basic Excl Extra (TTM)$-16.98
P/TBV (Quarterly)1.11x
P/B Ratio (Annual)1.11x
Book Value / Share (Annual)$4.75
Price vs S&P 500 (13W)-72.90%
Beta-708.75x
Revenue / Share (TTM)$0.00
ROE (TTM)-182.35%
52-Week Low$1.54
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ADILAdial Pharmaceuticals, Inc | — | — | — | — | $1.62 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing prescription treatments for addiction and related disorders. Its lead candidate, AD04, is an ondansetron-based therapy for alcohol use disorder, designed to address a significant unmet medical need in addiction medicine.